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High titers of HLA antibodies are associated with platelet refractori-ness, causing poor platelet increments after transfusions in a sub-set of patients with HLA antibodies. Currently, we do not know
the biological mechanisms that explain the variability in clinical respons-
es in HLA alloimmunized patients receiving platelet transfusions.
Previously we showed that a subset of anti-HLA IgG-antibodies induces
FcγRIIa-dependent platelet activation and enhanced phagocytosis. Here,
we investigated whether anti-HLA IgG can induce complement activa-
tion on platelets. We found that a subset of anti-HLA IgG induced com-
plement activation via the classical pathway, causing C4b and C3b dep-
osition and formation of the membrane-attack complex. This resulted in
permeabilization of platelet membranes and increased calcium influx.
Complement activation also caused enhanced α-granule release, as
measured by CD62P surface exposure. Blocking studies revealed that
platelet activation was caused by FcγRIIa-dependent signaling as well as
HLA antibody induced complement activation. Synergistic complement
activation employing combinations of monoclonal IgGs suggested that
assembly of oligomeric IgG complexes strongly promoted complement
activation through binding of IgGs to different antigenic determinants on
HLA. In agreement with this, we observed that preventing anti-HLA-IgG
hexamer formation using an IgG-Fc:Fc blocking peptide, completely
inhibited C3b and C4b deposition. Our results show that HLA antibod-
ies can induce complement activation on platelets including membrane
attack complex formation, pore formation and calcium influx. We pro-
pose that these events can contribute to fast platelet clearance in vivo in
patients refractory to platelet transfusions with HLA alloantibodies, who
may benefit from functional-platelet matching and treatment with com-
plement inhibitors. 
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ABSTRACT
Introduction
HLA alloantibodies can develop upon transfusion,1 transplantation2 and during
pregnancy.3,4 Leukoreduction of platelet transfusion products reduced HLA immu-
nization by more than 50 percent,5 however, 20-30% of patients receiving multiple
platelet transfusions still develop HLA alloantibodies.1,3,6 It is known that high titers
of HLA antibodies are associated with platelet refractoriness.7 About 12-15% of
patients, in need of chronic platelet transfusion support, become refractory to
platelet transfusions and repeatedly show poor incre-
ments of platelet counts caused by rapid clearance of the
transfused platelets.3,6 HLA-matched platelet transfusions
are commonly used for treatment of HLA alloimmunized
patients. However, treatment with HLA-matched platelet
concentrates is challenging due to the fact that it is often
difficult to find a sufficiently high number of compatible
donors for refractory patients. Current transfusion
approaches for HLA alloimmunized patients are exclu-
sively based on binding specificity of HLA antibodies but
do not take into account functional properties of circulat-
ing HLA antibodies. Here, we have further characterized
the pathogenic properties of different types of HLA-anti-
bodies. 
Previously, we showed that a subset of human mono-
clonal HLA antibodies and patient sera containing HLA
antibodies induce FcγRIIa-dependent platelet activation
and enhanced phagocytosis by macrophages.8 However, it
remains unclear to which extent this HLA antibody-medi-
ated activation of platelets contributes to platelet clearance
and which other mechanisms contribute to platelet clear-
ance in refractory patients. In the current study we have
focused on the role of complement activation by HLA
antibodies. 
Platelets have been shown to promote complement acti-
vation via several mechanisms. It has been reported that
activation of platelets, which leads to α-granule release
and subsequent CD62P surface exposure, triggers deposi-
tion of complement C3b. C3b can bind directly to CD62P
exposed on platelet surfaces, suggesting that platelet acti-
vation promotes complement deposition on platelets.9,10 In
this case, the alternative pathway of the complement cas-
cade is initiated, where binding of IgG and subsequent
C1q deposition is bypassed. Subsequent binding of C3b
facilitates further complement activation, finally leading
to the formation of a membrane attack complex (MAC),
also called the C5b-9 complex.9 Peerschke et al. also
showed that C1q can bind to agonist-activated platelets,
indicating a possible role for platelets in complement acti-
vation via the classical complement pathway.11 Platelet
activation can also induce complement activation in the
fluid phase, where the release of chondroitin sulfate by
activated platelets is the trigger.12 Also, binding of C3 to
activated platelets has been suggested to stimulate forma-
tion of platelet-leukocyte interactions.13 In addition, IgG-
complexes can induce platelet aggregation, which is
strongly enhanced by addition of C1q.14 Mouse 
monoclonal antibodies (mAbs) directed to beta-2
microglobulin (β2M) and a pan HLA mAb have been
shown to induce C3b binding and complement dependent
cytotoxicity (CDC) on platelets when added at high con-
centrations.15,16
Platelet transfusion-related adverse events might be
(partly) explained by complement activation in platelet
products as standard storage conditions have been shown
to induce complement activation with increasing C3a and
C4d levels found in platelet concentrates upon prolonged
storage.17
Here, we studied complement activation on platelets
induced by HLA antibodies. Human HLA mAbs and sera
from patients with refractory thrombocytopenia contain-
ing HLA antibodies were used to study the effect of com-
plement deposition, formation of a MAC, platelet activa-
tion and permeabilization. Our results show that a subset
of anti-HLA antibodies can induce complement activation
on platelets. We also showed that blocking pathways
leading to complement deposition on platelets, prevented
complement activation induced pathogenicity of HLA
antibodies. Based on our findings, we propose that func-
tional matching of platelet concentrates may be used to
further improve treatment of refractory patients with HLA
antibodies. Our results also suggest that complement-
directed therapeutic interventions may be utilized to
increase donor platelet survival in HLA-immunized refrac-
tory patients. 
Methods
Materials
Detailed information on materials used can be found in the
Online Supplementary Data.
Patient sera
Blood samples of patients refractory to platelet transfusion were
used following informed consent according to the Dutch estab-
lished codes of conduct for responsible use of patient material and
as approved by our institute.18 HLA antibody specificities in
patient sera were determined by single antigen bead assay on
Luminex platform (Labscreen SA, One Lambda, Inc.). Twelve sera
positive for HLA antibodies and negative for other platelet specific
antibodies were used.
Platelet isolation
Platelets were isolated from citrated whole blood from healthy
volunteers with known HLA type. All donors gave written
informed consent and blood was drawn in accordance with Dutch
regulations and after approval from the Sanquin Ethical Advisory
Board in accordance with the Declaration of Helsinki. Platelets
were isolated and washed as described before.19 Platelets were
resuspended in platelet assay buffer (10 mM HEPES, 140 mM
NaCl, 3 mM KCl, 0.5 mM MgCl2, 10 mM glucose and 0.5 mM
NaHCO3, pH 7.4).
Complement deposition and platelet activation
Platelets were used at a final concentration of 0.08*108
platelets/ml and mixed with indicated inhibitors, antibodies/sera
(heat inactivated for 30 min at 56°C, 25% of total sample volume)
and complement source (normal human serum) (25% of total vol-
ume) in platelet assay buffer. Mixtures were incubated for 30 min
at 37°C while shaking (300 rpm), and then fixed by adding
formaldehyde (final concentration of 1%). Platelets were washed
with platelet assay buffer and stained for flow cytometry. Anti-
CD42a-FITC or CD41-APC-Cy7 antibodies were used to gate for
platelets. Platelets were stained with mouse anti-human CD62P-
PE and mouse anti-human C3b-APC or mouse anti-human C4b-
APC. For measuring the formation of a MAC, platelets were
stained with rabbit anti-human C5b-9 antibody followed by the
secondary antibody chicken anti-rabbit Alexa 647. Mean fluores-
cent intensities and/or percentage positive platelets were meas-
ured using flow cytometer FACSCanto II (Becton Dickinson,
Franklin Lakes, NJ, USA).
Pore formation
Complement assay was initiated as described above. After 30
min incubation at 37°C, platelets were washed once and resus-
pended in assay buffer containing live/dead marker for 30 min at
room temperature (RT). Platelets were washed and stained with
anti-CD42a (for gating purposes), anti-C3b and CD62P and ana-
lyzed using flow cytometry.
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Calcium influx
Platelets were loaded with calcein violet and fluo-4 for 30 min
at RT, washed and resuspended in platelet assay buffer.
Complement activation assay was initiated as described above.
After 20 min incubation at 37°C, platelets were diluted in assay
buffer and calcium influx was measured immediately using flow
cytometry by measuring fluo-4 signal. Platelets were gated upon
their calcein violet fluorescence.
Data and statistical analysis
Flow cytometry data was analyzed using FlowJo version 10
(Ashland, OR, USA). Data are represented as either mean ± stan-
dard deviation (SD) or all data points are shown. Statistical analy-
ses were performed using GraphPad Prism 7 Version 7.02 (La Jolla,
CA, USA); the analyses used are specified in the respective figure
legends. 
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Figure 1. HLA mAb WIM8E5
induces C3b and C4b deposition
on platelets. (A) Platelets were
incubated with increasing con-
centrations of WIM8E5 and C3b
deposition was measured
employing flow cytometry.
Representative data from 1
donor. (B) C3b deposition on
platelets incubated with 20
mg/ml WIM8E5 were compared
to control platelets (no HLA anti-
body added). (n=7 different
donors). (C) Representative flow
cytometry graph of C4b deposi-
tion on platelets incubated with
WIM8E5 (20 mg/ml). (D) C4b
deposition on platelets from 7
different donors upon incubation
with 20 mg/ml WIM8E5. (E)
Comparison of C3b deposition
on platelets from 3 donors with
different amounts of WIM8E5
reactive antigens. Donor HLA
types are indicated in the figure,
strong WIM8E5 binding antigens
in green, weak binding antigens
in blue and non-binding antigens
in red. (F) Five donors heterozy-
gous for HLA-A2 (and no A3 or
A32) with different HLA expres-
sion levels (as measured with
anti-human IgG in the absence of
serum). Level of WIM8E5 binding
correlates with percentage C3b
positive platelets. Strong binding
antigens are indicated in green,
weak binding antigens in blue
and non-binding antigens in red.
MFI: mean fluorescence intensi-
ty. **P<0.01.
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R2 0.979
P <0.005
Results
HLA antibody WIM8E5 induces complement C3b and
C4b deposition on platelets
Human HLA mAbs recognizing different epitopes
encoded by different HLA class I subtypes (Online
Supplementary Table S1) were incubated with platelets
from donors with an HLA type matching the specificity of
the mAbs, in the presence of normal human serum.
Complement deposition of C3b on platelet surfaces
increased upon incubation with increasing concentrations
of HLA mAb WIM8E5 (specific for an epitope present on
all HLA-A antigens except for HLA-A3 and-A32 and with
reduced binding to HLA-A2) (Figure 1A). Statistically sig-
nificant increased C3b deposition was observed with 20
mg/ml WIM8E5 (Figure 1B). Also, C4b deposition on
platelet surfaces was significantly increased when
platelets were incubated with WIM8E5 (Figure 1C-D). A
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Figure 2. Combinations of HLA mAbs induce enhanced complement activation. (A) Four different HLA mAbs were incubated with HLA matched platelets both sep-
arately and in combination (20 mg/ml per antibody) and C3b deposition was measured. (B-C) Examples of C3b deposition induced by HLA mAbs separately and in
combination (20 mg/ml per HLA mAb). (D) C3b deposition on platelets of 2 donors by a combination of anti-HLA-A2 antibodies SN607D8 and SN230G6 at 0.0125
- 10 mg/ml. HLA donor 1: A2 A31 B60 HLA donor 2: A2 A68 B51 B57.
A
B
D
C
strong variation in the level of complement deposition of
C3b and C4b was observed between donors, whose vari-
ous HLA type matched in all cases with the specificity of
WIM8E5 (Figure 1B and D). A gene dosage effect was
observed; donors with two HLA-A antigen specificities
compatible with WIM8E5 binding induced more C3b dep-
osition compared to donors expressing one compatible
HLA-A antigen and HLA-A2 (with reduced binding or
affinity) (Figure 1E). Only minor C3b deposition was
observed when platelets from donors expressing only one
compatible HLA-A antigen (e.g., A11 and A32) were used
(Figure 1E right panel). Variable levels of C3b deposition
on platelets of 5 donors expressing HLA-A2 in combina-
tion with another WIM8E5 HLA-A-compatible antigen
were observed that correlated with WIM8E5 binding
(Figure 1F) This suggests that the level of IgG opsoniza-
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Figure 3. Complement deposition on platelets by HLA mAbs occurs via the classical complement pathway. (A) Pre-incubation of platelets with 50 mg/ml anti-C1q
inhibits C3b deposition (n=7), (B) and C4b deposition (n=7). (C) Dose response of increasing concentrations anti-C1q to inhibit C3b deposition induced by 20 mg/ml
WIM8E5 (n=4) (D) Effect of increasing concentrations of Fc:Fc blocking peptide DCAWHLGELVWCT on complement deposition induced by WIM8E5 (20 mg/ml) was
measured by C3b deposition (n=3), (E) and C4b deposition (n=4). (F) Effect of 200 mg/ml Fc:Fc blocking peptide on C3b deposition by WIM8E5 and
SN607D8/SN230G6 was compared to the irrelevant control peptide GWTVFQKRLDGSV (n=4). *P<0.05, **P<0.01.
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tion, probably largely affected by the number of available
epitopes for WIM8E5, is correlated with the level of
platelet complement activation.
Combinations of anti-HLA mAbs induce complement
deposition on platelets
Next, less broadly reacting anti-HLA human IgG1 mAbs
were tested for their ability to induce C3b deposition on
platelet surfaces. No C3b deposition was observed when
SN607D8, SN230G6, HDG8D9 and BRO11F6 were incu-
bated separately (Figure 2A; upper panel). However, by
combining these HLA mAbs, thereby mimicking the poly-
clonal nature of HLA alloimmunized patient sera, several
combinations promoted C3b deposition on platelets
(Figure 2A; lower panel and Figure 2B). This effect was
very strong when a combination of anti- HLA-A2 mAbs,
SN607D8 and SN230G6, were used (Figure 2B). Also,
combinations of monoclonal antibodies anti-HLA-A2
M. Rijkers et al.
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Figure 4. Platelet activation occurs via complement activation and FcγRIIa-
dependent activation. (A) C3b deposition and CD62P exposure were meas-
ured in the presence and absence of serum upon incubation with WIM8E5,
with or without pre-incubation of the platelets with Syk inhibitor (5 mM) or
FcγRIIa blocking antibody IV.3 (10 mg/ml). (B) In the presence of serum,
platelets were pre-incubated with anti-C1q (50 mg/ml), Syk inhibitor IV (5 μM)
or both and CD62P and C3b deposition were measured upon addition of
WIM8E5 (20 mg/ml). Representative flow cytometry graph, bar graph is mean
± SD (n=8). (C) Platelets were pre-incubated with IV.3 (10 mg/ml), Syk
inhibitor IV (5 mM) and/or the C5 inhibitor Eculizumab (10 mg/ml) in the pres-
ence of serum. C3b and CD62P exposure were measured upon incubation
with WIM8E5 (20 mg/ml). Representative flow cytometry graphs, bar graph
represents mean ± SD (n=8). Syk inh: Syk inhibitor; *P<0.05; **P<0.01;
***: P<0.005; ****P<0.001; ns: not significant.
A
B
C
(SN230G6) and anti-HLA-A11 (BRO11F6) (Figure 2B),
anti-HLA-A11 (BRO11F6) and anti-HLA-B52 (OK8F11), or
anti-HLA-B44 (DK7C11) and anti-HLA-B62 (OK8F11)
induced C3b deposition on platelets. Only when incubat-
ed together, the two anti-HLA-A2 antibodies SN607D8
and SN230G6, which bind to opposite sides of the peptide
binding groove in HLA-A2,20,21 were very effective in
inducing complement activation. Even at concentrations
as low as 0.2 µg/ml, these antibodies induced C3b deposi-
tion (Figure 2D). The levels of complement activation are
however dependent on the donor. Together, these results
suggest that the geometry of binding of anti-HLA antibod-
ies determines whether or not complement deposition can
occur.
Complement deposition induced by anti-HLA 
antibodies occurs via the classical pathway
Both classical- and alternative complement pathway
activation have been described to occur on platelets.9,11,22
To discriminate between these pathways, platelets were
Anti-HLA antibodies with complementary and synergistic interaction 
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Figure 5. HLA antibodies induce the formation of a MAC, pore formation and calcium influx. (A) Complement activation was induced by SN607D8/SN230G6 and
was inhibited by Eculizumab. Formation of a MAC was measured employing an anti-C5b-9 antibody. (n=4) (B) Representative flow cytometry plot showing
SN607D8/SN230G6 induced formation of the C5b-9 complex (solid line). In the presence of Eculizumab the formation of the C5b-9 complex is inhibited (dashed
line). (C) Pore formation upon incubation with increasing concentrations of SN607D8 and SN230G6 was measured using an impermeable dye, binding to free
amines: referred to as live/dead marker (L/D). (n=4) (D) Pore formation was blocked with anti-C1q. (n=4) (E) Representative flow cytometry plot of pore formation
measured by L/D marker upon complement activation by 10 mg/ml SN607D8/SN230G6 in presence and absence of 50 mg/ml anti-C1q. (F) Platelets were loaded
with fluo-4 to measure a calcium influx upon incubation with increasing concentrations of SN607D8 and SN230G6. On the y-axis, the percentage of Fluo-4 positive
platelets is depicted (n=4). (G) Pre-incubation of platelets with 50 mg/ml anti-C1q inhibited calcium influx induced by 10 mg/ml SN607D8/SN230G6. (n=4) (H)
Representative flow cytometry plot of fluo-4 signal induced by 10 mg/ml SN607D8/SN230G6 in the presence and absence of 50 mg/ml anti-C1q. Data are repre-
sented as mean ± SD. MFI: mean fluoresence intensity, *P<0.05; **P<0.01; ***P<0.005.
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pre-incubated with a blocking antibody directed to the tail
of C1q (anti-C1q), preventing binding of C1q to Fc-tails of
immunoglobulins. Complete blockage of WIM8E5
induced C3b and C4b deposition on platelet surfaces was
achieved by anti-C1q at a concentration of 50 mg/ml
(Figure 3A-B). The blocking effect of anti-C1q was dose
dependent (Figure 3C). These results indicate a crucial role
for C1q binding in WIM8E5 induced C3b and C4b depo-
sition, suggesting that complement activation occurs via
the classical pathway.
It has been described that IgG molecules can form hexa-
mers to which C1q can efficiently bind.23 Employing a
synthetic peptide shown to interfere with Fc-dependent
hexamer formation and subsequent complement deposi-
tion,23,24 we studied whether anti-HLA antibody-induced
complement deposition was blocked by this peptide. IgG-
Fc:Fc blocking peptide inhibited C3b and C4b deposition
by WIM8E5 or by the combination of SN607D8 and
SN230G6 in a dose dependent manner (Figure 3D-E). No
effects were observed with an irrelevant control peptide
(Figure 3F-G). Together, these results suggest that anti-
HLA antibody-induced complement deposition on
platelets involves Fc tail-mediated assembly of IgG hexa-
mers, creating a suitable binding platform for C1q.
Anti-HLA antibodies induce complement- and 
FcγRIIa-dependent platelet activation 
We have recently shown that a subset of anti-HLA
mAbs (including WIM8E5) can activate platelets directly
through FcγRIIa in the absence of a complement source.8
Under these conditions, WIM8E5-induced CD62P expo-
sure was completely blocked with either anti FcγRIIa-
blocking antibody IV.3 or through Syk inhibitor IV (which
blocks downstream signaling of FcγRIIa25) (Figure 4A).
Incubation of platelets with WIM8E5 in the presence of
serum as a complement source resulted in a marked
increase in CD62P exposure on platelets (Figure 4A).
Under these conditions, CD62P exposure was only slight-
ly inhibited by blocking FcγRIIa or with Syk inhibitor IV
(Figure 4A). These results suggest that in the presence of
complement activation, platelet activation is only partially
FcγRIIa-dependent. To study the effect of complement
activation on α-granule release, complement activation
was blocked with anti-C1q. This significantly inhibited
C3b deposition, but also only partly blocked α-granule
release as measured by CD62P exposure (Figure 4B).
However, a combination of Syk inhibitor and anti-C1q
blocked WIM8E5-induced CD62P exposure as well as
C3b deposition completely (Figure 4B). 
Previously, Wiedmer et al. described a mechanism
where the formation of a MAC on platelet surfaces
induces platelet activation and α-granule release caused by
calcium influx through the MAC.26 We used a C5 blocking
antibody (Eculizumab) to prevent cleavage of C5 and
thereby the formation of a MAC. Like anti-C1q,
Eculizumab partly inhibited CD62P surface exposure
(Figure 4C). WIM8E5-induced CD62P exposure was com-
pletely inhibited when Eculizumab was combined with
either Syk inhibitor IV or FcγRIIa blocking antibody IV.3
(Figure 4C). Similar results were obtained employing com-
binations of HLA mAbs (Online Supplementary Figure S1).
Together, these results suggest that in presence of a com-
plement source, platelet activation by anti-HLA antibodies
is dependent on formation of a MAC as well as FcγRIIa-
dependent signaling.
MAC formation leads to calcium influx
To confirm MAC formation, platelets activated with a
combination of SN607D8 and SN230G6 were stained
with an anti-C5b-9 antibody. As expected,
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Figure 6. IVIg and C1 esterase inhibitor inhibit complement deposition on platelets. (A-B) Platelets were incubated with increasing concentrations of IVIg (0-10
mg/ml), after which WIM8E5 (20 mg/ml) (A) or SN607D8 and SN230G6 (0.2 mg/ml) (B) were added. C3b deposition was measured on the platelet surfaces. (n=3).
(C-E) Platelets were pre-incubated with 0-600 μg/ml C1 esterase inhibitor. C3b deposition upon incubation with (C) 20 mg/ml WIM8E5 or (D) 0.2 mg/ml SN607D8
and SN230G6 was measured. (E) Inhibitory effect of C1 esterase inhibitor on C4b deposition was measured upon incubation with WIM8E5 (20 mg/ml) or SN607D8
and SN230G6 (0.2 mg/ml) (n=3).
A B
C D E
SN607D8/SN230G6 induced enhanced C5b-9 on the
platelet surface, which was blocked with anti-C1q (Figure
5A-B and Online Supplementary Figure S2).
Formation of a MAC is associated with cellular lysis
through its end product which is pore formation.27 To
measure the permeability of platelet membranes, a
live/dead marker (binding free amines, fluorescent signal
increases in case of damaged membranes due to accessi-
bility of intracellular amines) was added to platelets after
incubation with SN607D8/SN230G6. Incubation with
Anti-HLA antibodies with complementary and synergistic interaction 
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Figure 7. HLA antibody containing sera can induce complement activation on platelets. Twelve heat inactivated sera containing HLA antibodies were used to test
complement activation and Syk-dependent activation on platelets from 3 different donors. (A-C) Complement activation (in presence of serum) was induced in pres-
ence and absence of 25 mg/ml anti-C1q. (D-F) Syk-dependent activation (as measured by CD62P exposure) was induced in presence and absence of 5 mM Syk
inhibitor IV in the absence of a complement source. HLA typing of donor 1: A2 A3 B7, donor 2: A1 A2 B15:01 B35, donor 3: A11 A24 B35 B38. (G) IgG binding meas-
ured in absence of complement source employing an anti-human IgG antibody. (H) In green the antibodies present in sera matching the HLA typing of the platelet
donors, and in red the expressed HLA-antigens for which no matching antibodies are present are indicated. Dotted lines in panel E-F correspond to background val-
ues of heat inactivated serum controls (no anti-platelet antibodies present). MFI: mean fluorescence intensity.
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these HLA mAbs induced a large increase in membrane
permeability providing evidence for pore formation in
platelet membranes (Figure 5C). Anti-HLA antibodies
induced pore formation in a concentration-dependent
manner (Online Supplementary Figure S2) and pore forma-
tion could be inhibited by anti-C1q (Figure 5D-E).
Comparison of C3b deposition, C5b-9 complex formation
and pore formation revealed a clear correlation between
these three parameters upon incubation of platelets
derived of two different donors with increasing concentra-
tions of SN607D8/SN230G6 (Online Supplementary Figure
S2).  Under the same conditions, an increase in calcium
influx in platelets loaded with fluo-4 was measured
(Figure 5F-H). Together, these results suggest that comple-
ment activation induced by HLA antibodies leads to for-
mation of a MAC, with subsequent pore formation in
platelet membranes resulting in Ca2+ influx. 
Immunoglobulins (IVIg) and C1 esterase inhibitor
inhibit HLA antibody-induced complement activation 
IVIg can inhibit FcγRIIa-dependent platelet activation by
anti-HLA antibodies.8 Similar effects have been observed
in the context of heparin-induced thrombocytopenia.28,29
Here, we also tested if IVIg affects complement activation
and observed a dose-dependent inhibition of C3b deposi-
tion by IVIg (Figure 6A-B). Similarly, by inhibiting C1
employing the C1 esterase inhibitor, C3b and C4b deposi-
tion induced by HLA mAbs was inhibited (Figure C-E and
Online Supplementary Figure S1). These results show that
complement activation on platelets induced in vitro by
HLA mAbs can be inhibited by IVIg and C1 esterase
inhibitor in a dose dependent manner.
Sera containing HLA antibodies can induce 
complement activation on platelets, which is not 
correlated to Syk-mediated activation
In order to confirm our data obtained with human mon-
oclonal HLA antibodies, sera containing HLA antibodies
from 12 patients refractory to platelet transfusions were
tested for their ability to induce C3b deposition on
platelets (Online Supplementary Table S2). Depending on
the HLA type of the donor platelets, C3b deposition was
observed upon incubation with sera containing HLA anti-
bodies (Figure 7A-C). In agreement with the results
obtained for human mAbs, incubation with anti-C1q
blocked C3b deposition on platelet membranes (Figure
7A-C). In case of strong complement activation, 25 mg/ml
anti-C1q only partly inhibited C3b deposition. C3b depo-
sition, however, was completely blocked by anti-C1q
when the anti-HLA sera were diluted (Online
Supplementary Figure S4). This confirms that HLA antibod-
ies, as present in patient sera, induce complement activa-
tion via the classical pathway.
FcγRIIa-dependent α-granule release was also investi-
gated with the same donors and platelet donors, in
absence of complement source (Figure 7D-F). Some sera
induced both C3b deposition and FcγRIIa-dependent
platelet activation, however, similar to the results
obtained with HLA mAbs, there were also sera which
activated only one of these two pathways. These results
suggest that HLA antibodies may induce complement
activation and FcγRIIa-dependent platelet activation via
distinct mechanisms. To confirm that complement activa-
tion induced by HLA antibodies present in patients sera
correspond to that of HLA mAbs, platelet complement
activation and Syk-dependent activation were blocked.
Similar to results obtained with HLA mAbs (Figure 4 and
Online Supplementary Figure S1), both Syk-dependent and
complement-dependent platelet activation occurs when
platelets are incubated with HLA antibody containing sera
(Online Supplementary Figure S5). Furthermore, C3b depo-
sition induced by these sera could be inhibited employing
the IgG-Fc:Fc blocking peptide (Online Supplementary
Figure S6).
The level of IgG binding differed among sera and also
depended on the donor platelets used (Figure 7G and
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Figure 8. Proposed mechanism of anti-HLA antibody induced complement deposition. Upon binding of anti-HLA antibodies to HLA molecules on platelets, C1q can
bind to HLA-bound IgGs. This leads to initiation of the classical complement pathway which results in C4b and C3b deposition on the platelet surface. Eventually this
leads to the formation of a MAC which promotes the influx of Ca2+. Elevated intra-platelet Ca2+ levels induce platelet activation as measured by CD62P exposure. Anti-
HLA antibody-induced complement activation can be inhibited using anti-C1q blocking antibody or Eculizumab at the C1q of C5 level, respectively. Via a separate
mechanism binding of HLA antibodies to HLA molecules can cross-link with FcγRIIa and induce platelet activation independent of the complement pathway.
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Online Supplementary Figure S3). Although some associa-
tion between IgG binding and complement deposition
and FcγRIIa-dependent platelet activation was observed,
some sera displaying only limited IgG binding were still
capable of inducing complement activation or Syk-depen-
dent activation. This suggests that only a subset of anti-
HLA antibodies present in patient sera can induce C3b
deposition on platelets.  
Discussion
Development of HLA alloantibodies remains a major
cause of refractoriness to platelet transfusions. As yet, the
pathogenic properties of HLA alloantibodies have not
been sufficiently characterized. Here, we have shown that
HLA antibodies are capable of inducing complement acti-
vation on platelets, leading to C4b and C3b deposition on
platelet surfaces and the formation of a functional MAC.
It was previously shown that platelet activation can lead
to the binding of C3b,9 inducing complement activation
via the alternative pathway. We have previously shown
that HLA antibodies can induce FcγRIIa-dependent
platelet activation, leading to CD62P surface exposure.8
Therefore, we tested whether the complement activation
by HLA antibodies occurs via the classical pathway, or
whether CD62P surface exposure directly leads to C3b
binding followed by activation of the alternative comple-
ment pathway. Since a blocking antibody directed to C1q
completely blocked C3b and C4b deposition, complement
activation by HLA antibodies appears to be fully depend-
ent on the classical pathway. In line with this observation,
blocking FcγRIIa-dependent activation had no effect on
C3b deposition on platelets. Similar results were obtained
in patient sera containing HLA antibodies. Also, the ability
of HLA antibody-containing sera to induce complement
activation was not directly correlated to FcγRIIa-depen-
dent platelet activation. Some sera were capable of induc-
ing both complement- and FcγRIIa-dependent activation
of platelets.
We observed enhanced CD62P exposure in the samples
in which complement was activated. In the presence of a
complement source, CD62P exposure was only partly
blocked upon inhibition of FcγRIIa-signaling.
Simultaneous blocking of complement activation and
FcγRIIa-signaling resulted in complete inhibition of
platelet activation as measured by CD62P exposure. This
suggests that HLA antibodies can induce platelet activa-
tion by promoting complement deposition as well as
FcγRIIa-dependent signaling. We speculate that both
mechanisms may contribute to the rapid clearance of
platelets in refractory patients. 
In our study, we demonstrated that not all HLA mAbs
and patient sera induce complement activation to a similar
extent. Specific combinations of mAbs showed signifi-
cantly enhanced C3b deposition; strong, synergistic com-
plement deposition induced by incubation of platelets
with low concentrations of two distinct HLA mAbs
(SN607D8 and SN230G6) was observed. This suggests
that structural organization of platelet bound IgG is crucial
for initiation of the complement cascade. It has been
shown that C1q binds most efficiently to IgG hexamers,
for which Fc:Fc interactions are needed.23,30,31 In line with
these observations, we could completely block comple-
ment deposition induced by HLA mAbs by adding an IgG-
Fc blocking peptide24 described to prevent these Fc:Fc
interactions. The same blocking peptide inhibited C3b
deposition on platelets induced by HLA antibody-contain-
ing patient sera. These results suggest that the propensity
of polyclonal (patient)-derived HLA antibodies to form
IgG hexamers on the platelet surface provides a binding
platform for C1q which finally promotes the formation of
C5b-9 complexes on platelet membranes. Additional
properties of HLA antibodies such as specific subclass or
composition of the glycan in the Fc part of IgGs are
expected to potentially modulate complement activation
of HLA antibodies on platelets.
In this respect, it is interesting to note that glycosylation
of IgG1 has been described to affect the binding of IgG1
to C1q which also might affect the ability of individual
antibodies to induce complement activation.32 Altogether,
this might explain why only a subset of HLA mAbs and
patient sera containing HLA antibodies induce comple-
ment activation. Interestingly, sera containing HLA anti-
bodies matching the HLA type of the platelet donor did
not always induce complement activation. This may part-
ly be explained by differences in concentration and bind-
ing specificity of the different antibodies in these poly-
clonal sera, and varying levels of HLA expression on the
donor platelets used in this study.7 Also, the presence of
specific IgG subclasses might play a role, as different sub-
types bind with different affinity to C1q.33 In this study,
we show that low concentrations of specific HLA anti-
bodies can induce complement activation in a synergistic
manner. This observation suggests that depending on the
HLA profile and HLA density on donor platelets, specific
combinations of patient-derived HLA antibodies can
potently induce complement activation. Our results indi-
cate that the propensity of HLA antibodies to induce com-
plement activation is not per se related to the titer and
binding specificity of HLA antibodies in serum. Rather,
our findings suggest that the ability of HLA antibodies to
form hexameric IgG complexes on platelets determines
their ability to induce complement activation.
Ideally, the ability of HLA antibodies of individual
patients to induce platelet activation8 and /or complement
deposition on donor platelets should be assessed before
transfusion. Previous studies have shown that platelet
cross match does increase platelet recovery in patients, but
data on occurrence of hemorrhage and mortality are lack-
ing.34 Implementation of functional tests focusing on HLA
antibody-induced platelet activation and complement
deposition may have the potential to functionally stratify
platelet concentrates for specific HLA alloimmunized
patients. This would further increase the pool of suitable
donor platelets for treatment of HLA alloimmunized
patients who are currently dependent on treatment with
HLA-matched platelet concentrates. This would increase
transfusion safety, lower the costs and avoid delays in pro-
vision of donor platelets, which is important for transfu-
sion support in chronically transfused patients.
There are several treatment options for refractory
thrombocytopenia, which from an immunological per-
spective could target both FcγR- and complement-
dependent clearance of donor platelets. Immunoglobulins
(IVIg) could inhibit C3b deposition on platelets induced by
HLA mAbs. Inhibition of complement deposition by IVIg
has previously been shown in a number of autoimmune
disorders.35,36 A randomized trial in HLA alloimmunized
patients treated with IVIg revealed increased platelet-cor-
rected count increments one hour after transfusion com-
pared to placebo; however, no beneficial effects were
observed 24 hours after transfusion.37 Thus, IVIg might be
an effective way to prevent rapid platelet clearance
induced by HLA antibodies. Similarly, Eculizumab could
block formation of a MAC.38,39 Preliminary data of a clini-
cal trial showed that Eculizumab could overcome platelet
transfusion refractoriness in patients with HLA-alloanti-
bodies.40 The C3 inhibitor Compstatin was not tested
here, but is also used in clinical practice already41 and
might have a beneficial effect for patients refractory for
platelet transfusion caused by HLA alloantibodies. Also,
C1 esterase inhibitor, which blocks complement activa-
tion at the beginning of the complement cascade, inhibit-
ed C3b and C4b deposition induced by HLA mAbs.
Blocking complement activation at this point might be
even more beneficial than blocking after formation of C4b
and C3b. The potential beneficial effect of complement
inhibitors in refractory patients receiving platelet transfu-
sions needs to be confirmed in clinical studies.
In conclusion, in this study we have shown that HLA
antibodies can induce complement activation on platelets
through the classical complement pathway, as is schemat-
ically represented in the visual abstract. We propose that
C3b complement deposition induced by HLA alloantibod-
ies in refractory patients might contribute to platelet clear-
ance through their binding to C11b/CD18 on myeloid
cells. Ongoing complement activation on HLA-sensitized
platelets will lead to formation of a MAC allowing for
Ca2+-influx and subsequent platelet activation.
Importantly, these effects of HLA antibodies may not only
be prevented via HLA-matching between donors and
recipient antibodies, but also by functional matching,
since not all HLA antibodies are capable of inducing com-
plement activation. Furthermore, inhibition of comple-
ment activation, as currently studied in clinical trials, may
be of benefit to further optimize platelet support in HLA
immunized patients. 
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